Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Burning Rock Biotech ( (BNR) ) has provided an announcement.
Burning Rock Biotech announced the successful passing of all shareholder resolutions at its 2024 annual general meeting. Key decisions included the ratification of Ernst & Young Hua Ming LLP as the company’s auditor and the re-election of Yusheng Han and Gang Lu as directors. These resolutions reinforce the company’s governance and operational integrity as it continues to advance its technological innovations in the oncology sector.
More about Burning Rock Biotech
Burning Rock Biotech Limited is a company dedicated to the application of next generation sequencing (NGS) technology in precision oncology. The company offers NGS-based therapy selection testing for late-stage cancer patients and is advancing its cancer early detection services from research to clinical validation.
YTD Price Performance: -25.27%
Average Trading Volume: 33,924
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.26M
See more data about BNR stock on TipRanks’ Stock Analysis page.
